RxDoctor Payments Data

Samuel Koszer, MD

Neurology · Poughkeepsie, NYNPI 1982697975

Payments from drug & device makers

$21,576in general payments, 2019–2025

Across 347 payments — averaging $62.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$10K
  • Novartis$5K
  • Neurocrine Biosciences, Inc.$1K
  • AbbVie$1K
  • UCB, Inc.$506
  • Teva Pharmaceuticals USA, Inc.$423
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$6,37039%
  • Travel & lodging$2,41115%
  • Food & beverage$6,91642%
  • Education$7675%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,576 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$550,169
Medicare patients
1,118
Services billed
7,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab13$667,564
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$437,357
PanzygaImmun Glob G(Igg)-Ifas/Glycine11$362,855
GammakedImmune Globul G/Gly/Iga Avg 4617$259,561
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5014$201,935
Rebif RebidoseInterferon Beta-1a/Albumin12$162,970
Nurtec OdtRimegepant Sulfate87$145,571
EpidiolexCannabidiol (Cbd)33$136,951
AustedoDeutetrabenazine21$127,920
XywavSodium,calcium,mag,pot Oxybate12$121,362
Emgality PenGalcanezumab-Gnlm139$112,617
TecfideraDimethyl Fumarate12$108,838
Aimovig AutoinjectorErenumab-Aooe114$95,774
XcopriCenobamate66$94,688
Avonex Pen (4 Pack)Interferon Beta-1a11$85,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$138$667,56413 claims
PfizerPanzyga, Nurtec Odt$211$508,42798 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$79$437,35713 claims
UCB, Inc.Briviact, Neupro$506$142,93989 claims
Teva Pharmaceuticals USA, Inc.Austedo$423$127,92021 claims
BiogenTecfidera$90$108,83812 claims
AbbVieUbrelvy, Qulipta$1,093$66,97637 claims
Lundbeck LLCOnfi$62$60,23523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →